Eighteen years' experience with tumor treating fields in the treatment of newly diagnosed glioblastoma
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61383082%3A_____%2F25%3A00001622" target="_blank" >RIV/61383082:_____/25:00001622 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/23:00133390 RIV/00216208:11130/23:10455101 RIV/00843989:_____/23:E0110120 RIV/00064203:_____/23:10455101 and 2 more
Result on the web
<a href="https://pubmed.ncbi.nlm.nih.gov/36741707/" target="_blank" >https://pubmed.ncbi.nlm.nih.gov/36741707/</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3389/fonc.2022.1014455" target="_blank" >10.3389/fonc.2022.1014455</a>
Alternative languages
Result language
angličtina
Original language name
Eighteen years' experience with tumor treating fields in the treatment of newly diagnosed glioblastoma
Original language description
The prognosis of glioblastoma remains unfavorable. TTFields utilize low intensity electric fields (frequency 150–300 kHz) that disrupt cellular processes critical for cancer cell viability and tumor progression. TTFields are delivered via transducer arrays placed on the patients’ scalp. Methods: Between the years 2004 and 2022, 55 patients (20 female), aged 21.9–77.8 years (mean age 47.3±11.8 years; median 47.6 years) were treated with TTFields for newly-diagnosed GBM, and compared to 54 control patients (20 females), aged 27.0–76.7 years (mean age 51.4±12.2 years; median 51.7 years) (p=0.08). All patients underwent gross total or partial resection of GBM. One patient had biopsy only. When available, MGMT promoter methylation status and IDH mutation was detected. Results: Patients on TTFields therapy demonstrated improvements in PFS and OS relative to controls (hazard ratio: 0.64, p=0.031; and 0.61, p=0.028 respectively). TTFields average time on therapy was 74.8% (median 82%): median PFS of these patients was 19.75 months. Seven patients with TTFields usage ≤60% (23–60%, mean 46.3%, median 53%) had a median PFS of 7.95 months (p=0.0356). Control patients with no TTFields exposure had a median PFS of 12.45 months. Median OS of TTF patients was 31.67 months compared to 24.80 months for controls. Discussion: This is the most extensive study on newly-diagnosed GBM patients treated with TTFields, covering a period of 18 years at a single center and presenting not only data from clinical trials but also a group of 36 patients treated with TTFields as a part of routine clinical practice.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Frontiers in Oncology
ISSN
2234-943X
e-ISSN
—
Volume of the periodical
2025
Issue of the periodical within the volume
Jan
Country of publishing house
CH - SWITZERLAND
Number of pages
9
Pages from-to
1-9
UT code for WoS article
000923996600001
EID of the result in the Scopus database
2-s2.0-85147275259